¢ßÇѺöÅ×Å©³î·ÎÁö
 
 
HOME > NEWS
 
- BSD Medical
- i-CAT
- Ideal Implant
- Mevion
- Sensus HealthCare
- ViewRay
- Viveve
- Xoft
- HanBeam Tech


 
 
ÀÛ¼ºÀÏ : 15-02-06 13:10
iCAD ANNOUNCES MORE THAN 500 PATIENTS TREATED IN STUDY OF INTRAOPERATIVE RADIATION THERAPY (IORT) FOR EARLY-STAGE BREAST CANCER
 ±Û¾´ÀÌ : ÃÖ°í°ü¸®ÀÚ
Á¶È¸ : 5,722  
   http://www.xoftinc.com/documents/ExBRT_FINAL_PRESS_RELEASE.pdf [1798]
NASHUA, N.H., December 10, 2014 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft¢ç Axxent¢ç Electronic Brachytherapy (eBx¢ç) System¢ç. The study, ¡°A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study),¡± compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy.
¡°We have reached a key milestone in the ExBRT study, the largest IORT clinical study to date using the Xoft System. As IORT gains momentum among patients with early-stage breast cancer, we are seeing a wide range of sites, from large academic institutions to small community medical centers, expanding their breast care programs with the Xoft System,¡± said Ken Ferry, President and CEO of iCAD. ¡°iCAD is committed to providing advanced treatment options like IORT that have the potential to transform the treatment of cancer for thousands of patients.¡±
With the Xoft System, patients are treated with one dose directly to the tumor bed at the time of lumpectomy, thereby reducing the risk to nearby healthy tissue and organs such as the heart, lung, and ribs. Using the Xoft System also improves patient quality of life by reducing the number of treatments compared to EBRT, which usually requires 30-35 daily treatments over a period of 5-7 weeks. To date, more than 10,000 patients have been treated globally, across all clinical applications, with the Xoft System.
Researchers plan to enroll up to 1,000 patients across the U.S. and Europe. Currently, the study includes 23 active centers. Study subjects will be followed for 10 years after treatment to evaluate the long-term safety and efficacy of breast IORT with the Xoft System. The study will also assess cosmetic outcomes and quality of life for those treated with Xoft IORT.
¡°With more than 500 patients treated in the ExBRT study, we have reached an important milestone for assessing the long-term clinical value of IORT using a standardized protocol in patients with early-stage breast cancer,¡± said Helena Chang, M.D., Ph.D., University of California Los Angeles and co-principal investigator for the study. ¡°Enrollment to date is encouraging as treatment centers continue to provide appropriate patients with the option to complete a full dose of radiation therapy in a single treatment.¡±
Xoft will showcase the Xoft System at the 37th annual San Antonio Breast Cancer Symposium this week in booth #319 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray
as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.